BNTX
BioNTech SEDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive late-stage oncology readouts and clear partnership/licensing deals for next-gen mRNA assets lead to rapid re-rating; commercial launches or label expansions accelerate revenue and justify premium multiples.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +4.6.
What can break
Clinical/regulatory setbacks for oncology programs
Momentum
14
Value
41
Sentiment
80
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $115.00 · Bull $160.00 · Bear $75.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-03-15 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $139.96
Why
Momentum14 · Δ7d -1.4
Value41 · Δ7d +0.1
Sentiment80 · Δ7d +4.6
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
14
34% active weight
Current posture
7d trendSoftening
Δ7d
-1.4
Δ21d
-17.8
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
80
33% active weight
Current posture
7d trendImproving
Δ7d
+4.6
Δ21d
+11.5
Why this grade
Composite grade D. Momentum 13.9 / Value 41.1 / Sentiment 79.7
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$23.19B
Beta
1.49
Shares Out
240.46M
P/E (TTM) · Derived
-25.3
P/S (TTM)
6.30
P/FCF (TTM) · Derived
-19.09
Rev YoY
+22.0%
EPS YoY
-114.8%
Gross Margin
+85.6%
Op Margin
-29.6%
Net Debt
-$17.88B
Current Ratio
7.12
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology